|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema.
|
30764665 |
2020 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
To attribute data on changes in diabetic retinopathy (DR) severity during treatment of diabetic macular edema (DME) with vascular endothelial growth factor inhibitors (anti-VEGF), this study aimed to (1) examine the correlation between oxygen saturations in retinal vessels and the number of DR lesions on ultra-wide field color fundus photographs prior to anti-VEGF treatment and (2) compare changes in oxygen saturations in retinal vessels with changes in the number of DR lesions after a loading dose of three monthly intravitreal injections of 2.0 mg of aflibercept.
|
31715608 |
2020 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Substantial reductions in anti-vascular endothelial growth factor cost may make the ranibizumab therapy cost-effective within this range even for patients without baseline CI-DME.
|
31647496 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Across a wide range of clinical trials laser therapy was required as adjunctive/rescue treatment in approximately 20-50% of patients receiving anti-VEGF monotherapy for centre involving DME.
|
30575304 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
|
30959004 |
2019 |
|
Diabetic macular edema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anterior chamber AH sampling was performed at baseline at DEX injection time (T1), cataract surgery 8 weeks afterward (T2), and whenever DME relapsed (T3) in order to assess changes in IL-1β, IL-3, IL-6, IL-8, IL-10, MCP-1, IP-10, TNF-α, and VEGF levels.<i>Results</i>: IP-10 and MCP-1 levels significantly decreased at T2 (<i>p</i> = .034 and <i>p</i> = .044, respectively) compared to baseline (T1).
|
31418610 |
2019 |
|
Diabetic macular edema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current study aimed to address whether ripasudil, a Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor developed to treat glaucoma and ocular hypertension (OH), improves diabetic macular edema (DME) since it is known that ROCK upregulates vascular endothelial growth factor.
|
30842496 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective study in morphologic patterns of diabetic macular edema (diffuse retinal thickening n = 15; cystoid macular edema n = 38, and serous retinal detachment n = 17) recalcitrant to anti-vascular endothelial growth factor, treated with dexamethasone implant.
|
30832509 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differences in VEGF and other mediator expressions between treated and untreated DME were detected in VR samples.
|
30377797 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low-dose TA may be useful for patients with refractory DME resistant to anti-VEGF therapy.
|
31700228 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema.
|
31110222 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema.
|
31545295 |
2019 |
|
Diabetic macular edema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The only significant correlation was between vitreous VEGF level and blood HbA1c level in DME patients without subretinal fluid (r = 0.813, p = 0.002).
|
29524030 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
It seems most likely that local VEGF at the macula is the main cause of DMO.
|
30728488 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
|
31099498 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Funding and psychological burden are the main controllable factors for compliance to anti-VEGF therapy in DME.
|
30383436 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare sub-tenon steroid plus anti-VEGF injection with anti-VEGF injection solely in the treatment of resistant diabetic macular edema (DME).
|
29943100 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline Ocular Characteristics of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
|
30768213 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brolucizumab (Beovu<sup>®</sup>) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion.
|
31768932 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively analysed the records for 18 eyes that had or had not been vitrectomised but required an intravitreal dexamethasone implant for DMO after a poor response to anti-vascular endothelial growth factor.
|
30302004 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data.
|
29474302 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Today, the recommended treatment for severe nonproliferative and proliferative diabetic retinopathy is photocoagulation with an argon laser and intravitreal injections of anti-VEGF associated with, or not, focal laser for diabetic macular oedema.
|
31814880 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
|
30550375 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study.
|
31684007 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current treatments for DME include laser photocoagulation, corticosteroids and Vascular Endothelial Growth Factor (VEGF) antagonists, which are administered via intravitreal injection.
|
30328707 |
2019 |